Q&A Genmab 2022-05-23

	23/5 13:02 af Jan Van de Winkel	The data will be submitted for presentation at a future medical meeting, and, together with AbbVie, we will engage global regulatory authorities to determine next steps..
	23/5 13:01 af Jan Van de Winkel	Last month, we and AbbVie announced topline results from the first cohort of the Phase 1/2 study of epcoritamab in patients with relapsed/refractory large B-cell lymphoma who have received at least two prior lines of systemic therapy, including 38.9% who received prior treatment with CAR T therapy. In these high-risk, heavily pre-treated patients, epco demonstrated an ORR of 63.1%, with a median duration of response of 12 months..
	23/5 13:00 af Jan Van de Winkel	During the first quarter of 2022 we continued to build on our strong foundation to achieve our ambitious vision of transforming cancer treatment, with multiple advancements in our pipeline..
	23/5 13:00 af Jan Van de Winkel	Sure..
	23/5 13:00 af Helge Larsen/PI-redaktør	Can you give us a brief update on key figures and important events in Q1?
	23/5 12:59 af Jan Van de Winkel	Thank you for inviting us to interact once more. We look forward to an energizing session with plenty of smart questions as always.
	23/5 12:59 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	23/5 12:58 af Jan Van de Winkel	Hello, yes we are online.
	23/5 12:57 af Helge Larsen/PI-redaktør	Hi Jan van de Winkel. Are you online?
	23/5 12:30 af Helge Larsen/PI-redaktør	Denne Q&A starter kl. 13.